Cat.No. : CSC-CAR0001 Host Cell: THP-1
| Cat. No. | CSC-CAR0001 |
| Description | This cell line is a monoclonal cell line that is engineered to stably overexpress chimeric antigen receptor (CAR) targeting human CD19 (anti-CD19 CAR). |
| Gene | CD19 CAR |
| Host Cell | THP-1 |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Signaling pathway research 3. Drug screening and toxicology 4. Disease research |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
CAR T cell therapy for CD19 B cell malignancies may be limited by acute toxicities and immunoglobulin replacement due to persistent CAR T cell-induced B cell aplasia. Researchers developed a mouse model to investigate the toxicity mechanisms of Anti-hCD19-CAR and test safer CAR T cells. By transferring human CD19-specific mouse CAR T cells into mice with hemizygous hCD19 transgene expression, resembling human B cells, they observed undetectable tumor levels and B cell aplasia in recipients. Toxicities, including cytokine release syndrome, mirrored patient complications. IL-6, IFN-γ, and inflammatory pathway transcripts were enriched in affected tissues. Neutralization of IL-6 attenuated toxicity, while decreased microglial cells suggested neurotoxicity. This model will aid in evaluating strategies to enhance the safety of hCD19-specific CAR T cells.
Figure 1. Researchers investigated the impact of Anti-hCD19-CAR on CART-19 T cells activation. They cocultured CART-19 T cells with hCD19TG+/− B cells and observed increased CD marker expression and cytokine production. Additionally, CART-19 T cells effectively eliminated hCD19TG+/− B cells in vitro and in vivo, highlighting their potent anti-tumor activity.(Pennell CA, et al., 2018)
Explore the potential of Creative Biogene's Anti-hCD19-CAR(3G) Stable Cell Line - THP-1 for cancer research. Assess CAR-T cell activation, cytotoxicity, and cytokine production against CD19-positive malignancies. Accelerate your preclinical studies and advance cancer immunotherapy.
A: HEK293 cells were likely chosen for their suitability for genetic manipulation and molecular studies, allowing efficient knockdown of EHMT2 to investigate its role in epigenetic regulation and cellular processes.
A: Knockdown efficiency was likely assessed through methods such as qPCR, immunoblotting, or functional assays measuring EHMT2-mediated histone methylation, ensuring specific reduction of EHMT2 levels.
A: Characterization may involve analysis of changes in histone methylation patterns, gene expression profiles, cellular proliferation, differentiation, or response to external stimuli upon EHMT2 knockdown.
A: Quality control likely included confirmation of EHMT2 knockdown efficiency, assessment of off-target effects, and validation of phenotypic changes associated with EHMT2 depletion.
A: Comparative analysis with other cell lines or in vivo models helps elucidate the role of EHMT2 in epigenetic regulation, chromatin dynamics, and its involvement in various diseases such as cancer and neurodevelopmental disorders.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Exceptional performance! The Anti-hCD19-CAR(3G) Stable Cell Line in THP-1 cells has been instrumental in our immunotherapy research. Its stable expression of the third-generation chimeric antigen receptor (CAR) against hCD19 has provided robust and consistent activation of T cells, enhancing tumor cell killing efficacy.
Reliable and efficient! The stable expression of Anti-hCD19-CAR(3G) in THP-1 cells has facilitated precise targeting of hCD19-positive cancer cells, resulting in potent and specific antitumor responses. Its consistent CAR expression has ensured reliable and reproducible results across experiments.
Streamlining our studies! With the Anti-hCD19-CAR(3G) Stable Cell Line, we've been able to investigate the therapeutic potential of CAR-T cell therapy with confidence. Its stable expression of the third-generation CAR has simplified experimental workflows and accelerated the pace of our research.
Impressive performance! The Anti-hCD19-CAR(3G) Stable Cell Line has consistently exhibited robust CAR expression, surpassing our expectations. Its stable expression of the third-generation CAR has been pivotal in elucidating the mechanisms underlying CAR-T cell therapy and optimizing treatment strategies.
A valuable asset in cancer research! The Anti-hCD19-CAR(3G) Stable Cell Line has revolutionized our approach to studying immunotherapy. Its stable expression of the third-generation CAR has provided a solid foundation for investigating novel CAR designs and advancing the development of targeted cancer therapies.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
